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This review summarises some important new findings that implicate sphingosine-1-phosphate (S1P) as a potent tumorigenic and
angiogenic agent released from cancerous tumours into the tumour microenvironment. Also explored is the novel concept that
bioactive lipid signalling molecules, like S1P, can themselves be targets for rational drug design, thereby opening up an entire class of
lipidomic-based therapeutics for oncology and other human diseases.
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SPHINGOSINE-1-PHOSPHATE, A BIOACTIVE LIPID
WITH TUMORIGENIC EFFECTS
Until recently, phospholipids and their derivatives were considered
‘neutral’ in that they were thought either to serve a simple
structural role in cell membrane organisation or to provide energy
for beta oxidation, glycolysis and other metabolic processes. It has
only recently been appreciated that many lipids have significant
roles as bioactive signalling mediators. Good examples of such
bioactive lipids include: (i) the eicosanoids (such as the
cannabinoids and the leucotrienes), (ii) phospholipids and their
derivatives such as phosphatidic acid and platelet activating factor,
(iii) lysophospholipids such as lysophosphatidyl choline and
lysophosphatidic acid (LPA) and (iv) certain sphingolipids.
Sphingolipid signalling mediators represent a group of extra-
cellular and intracellular signalling molecules with pleiotropic
effects on important cellular processes, including cancer (Ogret-
men and Hannun, 2004). Figure 1 shows the key elements of the
sphingolipid signalling cascade, including the bioactive-lipid
mediators, ceramide (CER), ceramide-1-phosphate (C1P), sphingo-
sine (SPH) and sphingosine-1-phosphate (S1P). These mediators are
derived from sphingomyelin, which is present in the plasma
membranes of all mammalian cells.
Although much attention has been paid to S1P as a pleiotropic
mediator required for normal embryonic development, particu-
larly for cardiogenesis, vasculogenesis and angiogenesis (Liu et al,
2000), S1P has only recently been appreciated for its roles in
lymphocyte trafficking, inflammation, cardiovascular and neuro-
logical disorders and tumour biology (Hla, 2004; Gardell et al,
2006). The major source of S1P is that produced from SPH through
the action of sphingosine kinase (SPHK) (Taha et al, 2006). The
pleiotropic biological activities of S1P are mediated via a family
of G protein-coupled receptors (GPCRs) originally known as
endothelial differentiation genes (EDG). Five GPCRs have been
identified as high-affinity S1P receptors (S1PRs): S1P1/EDG-1,
S1P2/EDG-5, S1P3/EDG-3, S1P4/EDG-6 and S1P5/EDG-8 only
identified as late as 1998 (Lee et al, 1998). Many responses evoked
by S1P are coupled to different heterotrimeric G proteins (Gq,G i,
G1213) and the small GTPases of the Rho family (Gardell et al,
2006).
In the adult, S1P is released from platelets (Murata et al, 2000)
and mast cells to create a local pulse of free S1P (sufficient enough
to exceed the Kd of the S1PRs) for promoting wound healing
and participating in the inflammatory response. Under normal
conditions, the total S1P in the plasma is quite high (300–500nM);
however, it has been hypothesised\ that most of the S1P may be
‘buffered’ by serum proteins, particularly lipoproteins (e.g.,
HDL4LDL4VLDL) and albumin, so that the bio-available S1P
(or the free fraction of S1P) is not sufficient to appreciably activate
S1PRs (Murata et al, 2000). If this were not the case, inappropriate
angiogenesis and inflammation would result.
As early as the 1860s, Rudolf Virchow proposed that cancerous
tumours occur at sites of chronic inflammation. In 1986, HF
Dvorak speculated that tumours are ‘wounds that do not heal’
(Dvorak, 1986). One could argue that the ability of cancer cells to
release S1P into the tumour microenvironment is consistent with
the idea that cancerous tumours release mediators to trick the
body into thinking that it has a wound that needs the infiltration of
platelets, fibroblasts, mast cells and neutrophils for the purpose of
creating an inflammatory response. The infiltrating cells promote
further release of S1P into the tumour microenvironment with the
resulting manifestation of the tumorigenic and proangiogenic
effects of S1P (Figure 2).
SPHINGOSINE-1-PHOSPHATE IS TUMORIGENIC
It has been suggested that the balance between CER/SPH levels vs
S1P provides a rheostat mechanism that decides whether a cell is
sent into the death pathway (via CER and/or SPH) or is protected
from apoptosis by S1P. One of the key regulatory enzymes of the
sphingolipid rheostat mechanism is SPHK, whose role is to convert
the death-promoting sphingolipids, CER and SPH, into the
growth-promoting S1P. In most, but not all of the cell types
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www.bjcancer.comtested, S1P promotes cell proliferation and is involved in
chemotaxis and cytoskeletal rearrangement via the Rho signalling
system.
Cancer cells are notorious for being opportunistic in co-opting
key signalling systems. As such, they take advantage of the
sphingolipid rheostat by promoting conditions that favour the
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Figure 1 The extracellular signalling mediator, S1P, is produced by phosphorylation of SPH by SPHK. Sphingosine-1-phosphate exerts many of its
tumorigenic and angiogenic effects by acting as a ligand for the five GPCRs for S1P (S1P1–5). Sphingosine-1-phosphate is irreversibly metabolised to the
physiologically inert metabolites, ethanolamine-1-phosphate and hexadecanal. Sphingosine-1-phosphate can also be dephosphorylated by S1P phosphatases
(S1PP). Other key enzymes in the cascade are: sphingomyelinase (SMase), which produces CER and choline (not shown); ceramidase, which de-esterifies
CER to produce SPH (with a fatty acid product not shown); SM synthase; ceramide kinase (CKase); and ceramide-1-phosphate phosphatase (C1PP).
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Figure 2 S1P is a tumorigenic and angiogenic growth factor produced normally by blood platelets, mast cells and possibly fibroblasts in the tumour
microenvironment. Importantly, cancerous tumour cells upregulate the expression of SPHK1, which may greatly contribute to the putative increased levels of
S1P in the tumour microenvironment. The released S1P is able to act in an autocrine or paracrine manner on tumour cells (TCs) and vascular ECs to: (1)
promote DNA synthesis and resulting proliferation of both, (2) stimulate migration of cells enhancing the metastatic potential of TCs whereas promoting
EC-based angiogenesis and (3) protect TCs and ECs from proapoptotic chemotherapeutic agents. As an additional indirect angiogenic effect, S1P is
responsible for the release of proangiogenic growth factors (VEFG, IL-6 and IL-8) from TCs. The combined tumorigenic and angiogenic effects of S1P make it
an excellent target for anticancer therapy.
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upregulation of the expression of one isoform of the kinase,
SPHK1, the isoform that is thought to be responsible for S1P
release into the extracellular compartment. This raises the
possibility that sphk1 is an oncogene and, as a result, directs
attention to the kinase as a protein target for anticancer drug
discovery (Milstien and Spiegel, 2006).
The first studies proposing sphk1 as an oncogene observed that
NIH-3T3 fibroblasts stably transfected with the SPHK1 exhibited
enhanced cell proliferation accompanied by increased S1P
production (Vadas and Gamble, 1996). Cells overexpressing
SPHK1 escaped contact inhibition, a property commonly exhibited
by transformed cells. This observation is consistent with reports
showing that S1P enhances metastatic potential of human cancer
cell lines by promoting their motility and invasion (Takuwa, 2002;
Visentin et al, 2006). Moreover, cells transfected with SPHK can
produce tumours when orthotopically xenografted into nude mice,
and the resultant tumours are resistant to cytotoxic chemother-
apeutics (Pchejetski et al, 2005). These results are consistent with a
study showing that a small-molecule inhibitor of SPHK given i.p
can reduce tumour volumes in SCID mice receiving s.c. injections
of JC mammary adenocarcinoma cells (French et al, 2003).
Significantly, the concept that Sphk1 can be a novel oncogene is
further supported by the finding that SPHK1 is overexpressed in
many human solid tumours, such as those of the breast, colon,
lung, ovary, stomach, uterus, kidney and rectum (French et al,
2003; Johnson et al, 2005; Kawamori et al, 2006). As a
consequence, the increase in SPHK1 expression in tumour biopsies
has been correlated with a significant decrease in survival rate in
patients with glioblastoma multiforme (Van Brocklyn et al, 2005).
Importantly, it has been demonstrated that several human
tumour-derived cell lines become apoptotic when treated with
SPHK small-molecule inhibitors, and that their effectiveness can
be accounted for by their abilities to reduce S1P levels (Bektas
et al, 2005a). Similarly, downregulation of the kinase by siRNA
decreases resistance of melanoma cells to apoptosis, whereas the
protective effect of enhanced Bcl-2 expression has been attributed
to increased SPHK expression (Bektas et al, 2005a).
Taken together, these findings demonstrate an important
concept that S1P is a tumorigenic growth factor likely produced
by tumour cells themselves and that lowering the concentration of
S1P may be useful in anticancer therapy.
SPHINGOSINE-1-PHOSPHATE AND TUMOUR
ANGIOGENESIS
Angiogenesis is the process by which new blood vessels are formed
from existing vasculature. The angiogenesis process associated
with tumours (tumour angiogenesis) is considered to be a crucial
component of disease progression. Antiangiogenic therapeutics
is particularly attractive because vascular endothelial cells (ECs)
do not mutate as easily as do cancer cells; consequently, ECs are
less likely than cancer cells to gain resistance to prolonged
therapy, making them good potential targets for therapeutics. The
antiangiogenic approach to cancer has been greatly advanced by
the recent FDA approval of the antiangiogenic drug, bevacizumab
(Avastin
s, Genentech, South San Francisco, CA, USA) to treat
colon cancer as an adjunct to cytotoxic chemotherapy.
A growing body of recent evidence implicating S1P as one of the
most potent proangiogenic agents comes from studies directly
comparing S1P with agents such as VEGF and bFGF. Sphingosine-
1-phosphate stimulates DNA synthesis and chemotactic motility
of human venous ECs (HUVECs), whereas inducing differentiation
of multicellular structures, all of which is suggestive of S1P’s role
in early blood-vessel formation (Lee et al, 1999; Liu et al, 2000;
Argraves et al, 2004). Also, S1P promotes the migration of bone
marrow-derived EC precursors to neovascularisation sites (Annabi
et al, 2003). Cells that overexpress S1P1 are resistant to the
antiangiogenic agents thalidomide and Neovastat (Annabi et al,
2003). In addition, it has been demonstrated that substantial cross-
talk exists between S1P and other proangiogenic growth factors
such as VEGF, EGF, PDGF, bFGF and IL-8. For example, S1P
transactivates EGF (Shida et al, 2004) and VEGF2 receptors
(Spiegel and Milstien, 2003) and VEGF upregulates S1P1 receptor
expression (Igarashi et al, 2003). Also, S1P, acting via S1P1 and the
‘VEFG axis,’ is required for hind-limb angiogenesis and neovascu-
larisation (Chae et al, 2004).
The most direct in vivo evidence that S1P contributes to tumour
angiogenesis comes from our recent publication that focused on
a murine monoclonal antibody (mAb) designed to neutralise
extracellular S1P by molecular absorption (Visentin et al, 2006). In
various in vitro assays using HUVECs, the anti-S1P mAb
neutralised tube formation, migration of vascular ECs and
protection from cell death, each of which is S1P-induced.
Sphingosine-1-phosphate increased new capillary growth into
Matrigel plugs implanted in mice, an effect that was neutralised
by the systemic administration of the anti-S1P mAb. The mAb
substantially neutralised bFGF- and VEGF-induced angiogenesis in
a murine Matrigel plug assay, and the antibody mitigated S1P
stimulated the release of proangiogenic cytokines (VEGF, IL-8 and
IL-6) from tumour cells in vitro and in vivo. Importantly, mice
xenografted with orthotopically placed human cancer cells
exhibited substantial retardation of tumour progression with
anti-S1P mAb treatment. This was demonstrated in murine models
of human breast, ovarian and lung cancer and in one allograft
model of murine melanoma (Visentin et al, 2006).
TARGETING S1P AS A LIPIDOMIC-BASED
THERAPEUTIC INTERVENTION
It is now well accepted to target the protein ligand of a receptor
(e.g., Avastin targets VEGF; Remicade and Humira target TNFa)
for the purpose of intervening in the signalling cascade that would
otherwise have been activated by the ligand–receptor interaction.
Monoclonal antibodies like Avastin have been particularly useful
as molecular sponges to selectively absorb and neutralise the
protein ligands that would otherwise activate receptors.
The anti-S1P mAb is potentially valuable in that it is a reagent
that targets a bioactive-lipid ligand, in this case S1P. By
comparison with large protein ligands like VEGF (35000–
44000Da), the lipid target, S1P, is a small molecule (379Da)
and, as a consequence, has only one epitope (i.e., the polar head
group) to target for antibody recognition (inset of Figure 1).
Unlike the successful work with anti-PGE2mAbs (Portanova et al,
1996), academics and industry researchers have not been
successful in developing mAbs that inhibit bioactive lysolipids
like S1P and LPA with antibody specificity, affinity and other
performance characteristics suitable for preclinical proof-of-
concept work. This leads one to argue that sphingomab may be
a drug of an emerging discipline that may be termed lipidomic-
based therapeutics.
With a few notable exceptions (e.g., folic acid targeted by
methotrexate), the vast majority of the 4500 molecular drug targets
are proteins. Second to protein targets are nucleic acids, accounting
for about 2% of the total targets. The focus on proteins was a natural
consequence of our evolving understanding of biochemistry, which
allowed researchers to identify potential protein targets involved in
key metabolic and signalling pathways. Some of the first drugs
developed by the rational drug design approach to the scientific
method came after the discovery of key enzymes, receptors and ion
channels as they emerged in the basic science literature. One can
argue that target identification now is driven by the technological
developments of proteomics and genomics, both of which reflect
our persistent ‘protein-centric’ view of drug discovery.
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emerged (Wenk, 2005) and provides new opportunities for drug
discovery. As was the case for proteomics and genomics, tools of
measurement led the way. For lipidomics, the development of
electrospray tandem mass spectrometry and other tools has
facilitated our understanding of the cellular lipidome, and we
now believe that there are over 1000 members of the lipidome,
opening up an entire array of new potential targets for therapeutic
interventions.
It has been recognised that alterations in lipid metabolism can
lead to cancer, cardiovascular disease, diabetes, neurodegenerative
disorders, immune function, pain, mental disorders and inflam-
mation. However, only as a consequence of our recent appreciation
that bioactive lipids are bona fide signalling molecules have key
members of the functional lipidome been viewed as targets for
rational drug design. The best example of signalling lipids to target
might be prostaglandins as proinflammatory agents. The Cox-2
inhibitors designed to mitigate prostaglandin production not only
are effective NSAIDs but are now proving useful in clinical trials
for cancer therapy.
Of late, the attractiveness of the sphingolipid group of bioactive
lipids as targets has been fuelled by the recent discovery, beginning
largely in the mid-1990s, that many small-molecule lipid mediators
are ligands for GPCRs (e.g., S1P and LPA on EDG receptors), ion
channels (e.g., SPC action on SCaMPER) and/or modulators of
key kinases (e.g., SPH action on PKC) and transcription factors
(e.g., LPA action on PPARg).
When searching the functional lipidome for new anticancer targets,
researchers with a protein-centric view focus on the lipid proteome,
rather than on the lipidome itself. As such, in the antisphingolipid-
therapeutics arena, several pharmaceutical and biotechnology com-
panies have chosen the classical approach of targeting enzymes of the
sphingolipid biosynthetic pathway, such as SPHK1, or one or more of
the five GPCRs identified for S1P (S1P15).
Unfortunately, targeting SPHK is somewhat complicated by the
finding that SPHK1 and SPHK2 may have opposite actions
(Maceyka et al, 2005a). Sphingosine kinase1 is thought to be
translocated to the surface membrane and to produce/release the
extracellular S1P that is tumorigenic and proangiogenic. Thus,
SPHK1 is thought to produce the extracellular S1P that protects
cancer cells from proapoptotic cytotoxics (Figure 2). On the other
hand, SPHK2 induces apoptosis and inhibits growth (Maceyka
et al, 2005b). The SPHK2 is likely to produce S1P exclusively for
intracellular signalling.
Because of the divergent roles of the two SPHK isoforms, a
SPHK-targeted anticancer therapeutic would have to selectively
inhibit SPHK1 and not SPHK2. This may prove to be difficult,
as both enzymes have five highly conserved domains and the
resulting high-percent identity in their amino-acid sequences. In
addition, several splice variants of both isoforms have been
characterised and a third isoform of SPHK has been recently
identified (Bektas et al, 2005b), thus further complicating target
selectivity. Novagen’s anticancer genestein derivative, phenoxo-
diol, currently in Phase 3 trials, is thought to have some activity as
an inhibitor of SPHK (Gamble et al, 2006).
Other SPHK-independent sources of S1P have been suggested.
One such player is the exoenzyme, autotaxin, which is capable of
producing S1P from SPC (Clair et al, 2003). Potential additional
sources of S1P like the autotaxin story may explain why sphk1-null
mice exhibited no significant changes in tissue S1P levels even
though tissue SPHK activity was nearly eliminated (Allende et al,
2004). However, autotaxin KO mice exhibited no significant
changes in S1P levels either (van Meeteren et al, 2006); so, it
remains unclear as to how dominant SPHK is as the sole source of
tissue or blood S1P.
Another classical approach to intervening in the sphingolipid
pathway is preventing S1P from interacting with its compliment of
S1PRs. The potential success of this strategy has been simulated by
studies showing that the antineoplastic and antiangiogenic effect of
the sphingolipid analogue, FTY720 (Lamontagne et al, 2006) can
be attributed to its downregulation of four of the five S1PRs
(Cuvillier and Levade, 2003). One complication to the antireceptor
approach is that not all S1PRs mediate tumorigenic responses.
Although S1P1 and S1P3 are responsible for the proproliferative,
promigratory and antiapoptotic effects of S1P, S1P2 has been
shown to have the opposite effects on cell migration and other
responses (Goparaju et al, 2005; Sanchez et al, 2005). Thus, as is
the case with SPHKs, targeting S1PRs may be complicated by the
presence of multiple isoforms with opposing actions on tumour
cells, and selectivity of receptor antagonism will be a key element
in successful sphingolipid receptor-based therapeutic interven-
tions.
A more direct approach that avoids these limitations is the
prevention of ligand binding to all cognate receptors, the approach
that could be used by the highly specific mAb to S1P. Preclinical
data demonstrate that this approach deprives growing tumour cells
of important growth and survival factors and largely mitigates
tumour angiogenesis (Visentin et al, 2006). Because of the
important role of sphingolipids in cancer progression, it has been
argued that sphingolipid-based therapeutics will be the next
generation of cancer treatments (Milstien and Spiegel, 2006).
CONCLUSION
The use of the anti-S1P mAb as a research tool has provided strong
evidence that S1P has several mechanisms of action in promoting
cancer, including: (i) direct effects of S1P on tumour-cell growth
and metastatic potential, (ii) direct angiogenic effects on ECs in
their tumour angiogenesis roles and (iii) indirect angiogenic
effects of S1P in stimulating the release and action of other
proangiogenic growth factors such as VEGF (Figure 2). This work,
as well as recent strides in our understanding of the cellular
lipidome, gives credence to an emerging area of drug discovery
called lipidomic-based therapeutics that directly targets pleiotropic
bioactive lipids involved in cancer as well as other disorders.
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